Deerfield takes translational partnership model to Harvard with $100M deal
In an increasingly generous effort to bridge some of America’s best biomedical research with the commercial world, Deerfield has committed $100 million to a new translational research alliance with Harvard University.
Through a company dubbed Lab1636, Deerfield will fund a number of R&D projects that bolster drug discovery and development, for example studies to explicate the biology of disease, validate therapeutic targets, or achieve IND-enabling proof-of-concepts. In addition, the investment firm will help university researchers liaise with outside companies for licensing deals, as well as nurture new startups coming out of the university.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
